keyword
MENU ▼
Read by QxMD icon Read
search

tocilizumab

keyword
https://www.readbyqxmd.com/read/29334721/efficacy-and-safety-of-tocilizumab-in-korean-patients-with-active-rheumatoid-arthritis
#1
Han Joo Baek, Mie Jin Lim, Won Park, Sung Hwan Park, Seung-Cheol Shim, Dae-Hyun Yoo, Hyun Ah Kim, Soo Kon Lee, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha, Yeong-Wook Song
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks...
January 17, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29329563/pm2-5-induced-oxidative-stress-increases-intercellular-adhesion-molecule-1-expression-in-lung-epithelial-cells-through-the-il-6-akt-stat3-nf-%C3%AE%C2%BAb-dependent-pathway
#2
Chen-Wei Liu, Tzu-Lin Lee, Yu-Chen Chen, Chan-Jung Liang, Shu-Huei Wang, June-Horng Lue, Jaw-Shiun Tsai, Shih-Wei Lee, Shun-Hua Chen, Yi-Fan Yang, Tzu-Yi Chuang, Yuh-Lien Chen
BACKGROUND: Epidemiological studies have shown that ambient air pollution is closely associated with increased respiratory inflammation and decreased lung function. Particulate matters (PMs) are major components of air pollution that damages lung cells. However, the mechanisms remain to be elucidated. This study examines the effects of PMs on intercellular adhesion molecule-1 (ICAM-1) expression and the related mechanisms in vitro and in vivo. RESULT: The cytotoxicity, reactive oxygen species (ROS) generation, and monocyte adherence to A549 cells were more severely affected by treatment with O-PMs (organic solvent-extractable fraction of SRM1649b) than with W-PMs (water-soluble fraction of SRM1649b)...
January 12, 2018: Particle and Fibre Toxicology
https://www.readbyqxmd.com/read/29325462/tocilizumab-treatment-in-patients-with-rheumatoid-arthritis-is-associated-with-reduced-fibrinogen-levels-and-increased-blood-loss-after-total-knee-arthroplasty
#3
Hitoshi Imamura, Shigeki Momohara, Koichiro Yano, Yu Sakuma, Masanori Nakayama, Haruki Tobimatsu, Katsunori Ikari
OBJECTIVE: Because IL-6 has been associated with activation of the coagulation cascade and upregulation of fibrinogen transcription, we retrospectively tested the hypothesis that patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ) may lose more blood when undergoing total knee arthroplasty (TKA). METHODS: This study included 115 RA patients who underwent primary TKA and were preoperatively tested for fibrinogen levels. The blood volume of each patient was calculated using the Nadler formula, and estimated blood loss after TKA was calculated as the change between preoperative and postoperative hematocrits...
January 11, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29320845/subcutaneous-administration-of-tocilizumab-is-effective-in-myointimal-hyperplasia-remodelling-in-refractory-takayasu-arteritis
#4
A Lo Gullo, G Mandraffino, C O Aragona, A Molica Colella, A Saitta, E Imbalzano
Takayasu arteritis (TA) is a chronic inflammatory disease of unknown origin that involves large and mediumsized arteries, primarily the aorta and its major branches. TA is a therapeutic challenge because corticosteroids and conventional immunosuppressive agents are not always effective or safe. Interleukin 6 (IL-6) has emerged as a key cytokine in the pathogenesis of TA and its serum levels have been shown to well correlate with disease activity. We report a 19 years old female patient with TA refractory to conventional immunosuppressive agents, successfully treated with subcutaneous tocilizumab, a humanized monoclonal antibody against IL-6 receptor, in which ultrasonography (US) was used as imaging tool to follow up the patient...
December 21, 2017: Reumatismo
https://www.readbyqxmd.com/read/29314272/eruptive-nevi-under-tocilizumab-first-case-report-and-data-analysis
#5
Y Mansour, A Lambert, M Tebacher-Alt, J L Pasquali, D Lipsker
we would like to draw attention to an unusual side effect of tocilizumab (TOC), a humanized monoclonal antibody directed against the interleukin 6 (IL-6) receptor, approved for the treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). This article is protected by copyright. All rights reserved.
January 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29314183/fixed-dosing-of-intravenous-tocilizumab-in-rheumatoid-arthritis-results-from-a-population-pharmacokinetic-analysis
#6
Carla Bastida, Virginia Ruiz-Esquide, Mariona Pascal, Aurelia H M de Vries Schultink, Jordi Yagüe, Raimon Sanmartí, Alwin D R Huitema, Dolors Soy
AIM: Intravenous tocilizumab is currently dosed on body weight although a weak correlation between body weight and clearance has been described. The aim of the study was to assess the current dosing strategy and provide a scientific rational for dosing using a modeling and simulation approach. METHODS: Serum concentrations and covariates were obtained from intravenous tocilizumab treated subjects at a dose of 4, 6 or 8 mg every 28 days. A population pharmacokinetic analysis was performed using nonlinear mixed effects modeling...
January 4, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29306313/-keratoconjunctivitis-associated-with-atopic-dermatitis-treated-with-tocilizumab
#7
Celia Raga Jiménez, Tamara Álvarez Martín, Raúl Ferrando Piqueres, Gerard Pitarch Bort
No abstract text is available yet for this article.
January 1, 2018: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29303704/golimumab-in-refractory-uveitis-associated-to-juvenile-idiopathic-arthritis-multicentre-study-of-7-cases-and-literature-review
#8
REVIEW
Natalia Palmou-Fontana, Vanesa Calvo-Río, José Luis Martín-Varillas, Carlos Fernández-Díaz, Marina Mesquida, Alfredo Adán, María Victoria Hernández, Miguel Cordero-Coma, Olga Maiz Alonso, David Díaz-Valle, Carlos Fernández-Cid, Oscar Ruiz-Moreno, José Luis Hernández, Miguel Angel González-Gay, Ricardo Blanco
OBJECTIVES: To assess the efficacy of golimumab (GLM), a fully humanised anti-TNF-α monoclonal antibody, in refractory juvenile idiopathic arthritis (JIA)-associated uveitis. METHODS: This was a multicentre study of JIA-associated uveitis refractory to standard synthetic immunosuppressive drugs and in most cases to other anti-TNF-α agents. Results were expressed as mean±standard deviation or as median (range or interquartile range). The Wilcoxon signed-rank test was used to compare continuous variables...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29303703/reasons-for-inactive-disease-and-flare-in-systemic-onset-juvenile-idiopathic-arthritis-patients-during-tocilizumab-treatment
#9
Mikhail M Kostik, Eugenia A Isupova, Irina A Chikova, Margarita F Dubko, Vera V Masalova, Ludmila S Snegireva, Olga V Kalashnikova, Vyacheslav G Chasnyk
OBJECTIVES: The aim of our study was to evaluate disease courses and outcomes of sJIA children undergoing tocilizumab (TCZ) treatment, and to establish the predictors which distinguish inactive disease and disease flares. METHODS: Our retrospective study included 48 active sJIA children who were refractory to different anti-rheumatic drugs and who were then started on TCZ. The effectiveness of TCZ was assessed by the changes of sJIA attributed signs and symptoms and the remission was judged according to the Wallace (2004) criteria...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29303702/comparison-of-the-risks-of-hospitalisation-for-cardiovascular-events-in-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-and-etanercept
#10
Elena Generali, Greta Carrara, Carlo Selmi, Suzanne M M Verstappen, Antonella Zambon, Alessandra Bortoluzzi, Carlo Alberto Scirè
OBJECTIVES: To verify if tocilizumab (TCZ) is associated with an increased risk of cardiovascular (CV) events compared with etanercept (ETN) in rheumatoid arthritis (RA). METHODS: This is a retrospective cohort study on administrative healthcare databases (AHD) in Italy. Patients were identified using a validated algorithm based on AHD. Exposure to specific drugs was estimated by the drug prescription recorded in the AHD. The occurrence of acute CV events (myocardial infarction, stroke, other CV events) was derived from the hospital discharge forms...
December 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#11
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29287589/rapid-clinical-improvement-of-amyloid-a-amyloidosis-following-treatment-with-tocilizumab-despite-persisting-amyloid-deposition-a-case-report
#12
Akira Yamagata, Takahiro Uchida, Yuji Yamada, Takashi Nakanishi, Kazue Nagai, Toshihiko Imakiire, Naoki Oshima, Hiroo Kumagai
BACKGROUND: Amyloid A amyloidosis is one of the most common forms of amyloidosis. It is secondary to rheumatoid arthritis, which is difficult to manage and has a poor prognosis. We present a patient with rheumatoid arthritis and amyloid A amyloidosis who was treated with tocilizumab, a humanized monoclonal antibody against interleukin 6 receptor, resulting in improvement in both proteinuria and gastrointestinal symptoms; however, amyloid deposition remained. CASE PRESENTATION: A 67-year-old woman who had previously been treated for rheumatoid arthritis presented with abdominal pain and diarrhea...
December 29, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/29279488/tafro-syndrome-with-disseminated-intravascular-coagulation-successfully-treated-with-tocilizumab-and-recombinant-thrombomodulin
#13
Yusuke Takayama, Tetsuya Kubota, Yoshitaka Ogino, Hiroshi Ohnishi, Kazuto Togitani, Akihito Yokoyama
TAFRO syndrome is a systemic inflammatory disorder that is characterized by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly. Although thrombocytopenia is one of the major features of TAFRO syndrome, complications of disseminated intravascular coagulation (DIC) are not common. The therapeutic strategy for TAFRO syndrome complicated by DIC has not been established. We herein describe a case of TAFRO syndrome with DIC that was successfully treated with tocilizumab (an anti-IL-6 receptor antibody) and recombinant thrombomodulin (rTM)...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#14
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29260457/correction-to-tocilizumab-a-review-in-rheumatoid-arthritis
#15
Lesley J Scott
The article Tocilizumab: A Review in Rheumatoid Arthritis, written by Lesley J. Scott, was originally published Online First without open access. After publication in volume 77, issue 17, pages 1865-1879 F. Hoffmann-La Roche Ltd requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by F. Hoffmann-La Roche Ltd. Further details may be found at http://www.medengine.com/Redeem/68FBF06068F81EA7 . The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4...
December 19, 2017: Drugs
https://www.readbyqxmd.com/read/29260102/tocilizumab-as-a-steroid-sparing-agent-for-the-treatment-of-graves-orbitopathy
#16
David J Russell, Lilly H Wagner, Stuart R Seiff
Purpose: To describe the effect of tocilizumab in two patients with thyroid associated orbitopathy (TAO). Observations: We present two patients with TAO who could not tolerate corticosteroids and had a reduction in clinical and laboratory markers of inflammatory activity with subsequent tocilizumab therapy. Conclusions and importance: The IL-6 receptor antibody tocilizumab is a promising candidate for the treatment of TAO because it selectively targets a key inflammatory mediator and has a favorable side effect profile...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29259711/recent-advances-in-the-treatment-of-skin-involvement-in-systemic-sclerosis
#17
REVIEW
Yoshihide Asano
Skin fibrosis is a devastating clinical condition commonly seen in skin-restricted and systemic disorders. The goal of skin fibrosis treatment is the restoration of abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems. Among various skin fibrotic conditions, the molecular mechanisms underlying dermal fibroblast activation have been mostly well studied in systemic sclerosis (SSc)...
2017: Inflammation and Regeneration
https://www.readbyqxmd.com/read/29251032/safety-and-effectiveness-of-subcutaneous-tocilizumab-in-patients-with-rheumatoid-arthritis-in-a-real-world-clinical-setting
#18
Tatsuya Atsumi, Keishi Fujio, Kunihiro Yamaoka, Minako Tomobe, Kazuyuki Kuroyanagi, Hideto Kameda, Yoshiyuki Moriguchi
OBJECTIVES: To evaluate the safety and effectiveness of subcutaneous tocilizumab (TCZ-SC) in a real-world clinical setting in Japan. METHODS: This single arm, 26-week prospective observational study enrolled patients with RA who were either TCZ naïve or switched from TCZ-IV to TCZ-SC (TCZ-IV-SC group) (UMIN Clinical Trials Registry UMIN000011102). All patients received TCZ-SC 162 mg every 2 weeks and data were collected until week 26 or discontinuation. RESULTS: Overall 784 (78...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29251027/efficacy-and-safety-of-tocilizumab-with-inhibition-of-interleukin-6-in-adult-onset-still-s-disease-a-meta-analysis
#19
Yubo Ma, Meng Wu, Xu Zhang, Qing Xia, Jiajia Yang, Shengqian Xu, Faming Pan
OBJECTIVE: Tocilizumab (TCZ) is the only available biologic inhibiting interliukine-6 presently, and emerging evidences have figured that elevated serum level of interleukine-6 is a crucial link of the pathogenesis of adult-onset Still's disease (AOSD). However, evidence about the efficacy and safety of TCZ in AOSD with strong power is still scarce. Thus, this meta-analysis was conducted to synthetically assess the efficacy and safety of TCZ on AOSD. METHODS: PubMed, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure and Chinese Biological Medical Literature database were comprehensively searched up to 31 July, 2017 for the pertinent studies...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29248883/necrotising-soft-tissue-infection-without-systemic-toxicity-in-a-patient-with-rheumatoid-arthritis-treated-with-tocilizumab
#20
Saki Manabe, Hidetaka Yanagi, Hideki Ozawa, Atsushi Takagi
A Japanese woman aged 76 years with rheumatoid arthritis treated with prednisolone and tocilizumab presented with a 2-day history of redness and pain in her right thigh. She was hospitalised with a primary diagnosis of cellulitis and antimicrobial therapy was initiated. She had been stable until the fourth day of admission, when the swelling of her right thigh rapidly worsened and demonstrated purpura; she was subsequently unable to walk because of the pain. A diagnosis of necrotising soft tissue infection (NSTI) was made and extensive debridement was performed...
December 15, 2017: BMJ Case Reports
keyword
keyword
5841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"